Details of the Drug Reposition

General Information of This Drug (ID: DM8YUJT)

Drug Name
CWHM-12   DM8YUJT
Synonyms
cwhm-12; CWHM12; 1564286-55-0; (3S)-3-(3-bromo-5-(tert-butyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid; CHEMBL3319237; CWHM 12; SCHEMBL15475283; GTPL10495; AOB2397; EX-A850; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid; BDBM50497716; MFCD28385850; AKOS027423695; CS-3537; NCGC00390566-03; AS-16717; HY-18644; J-690209; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-(2-(3-hydroxy-5-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-ylamino)benzamido)acetamido)propanoic acid
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pulmonary fibrosis DISQKVLA CB03.4 Preclinical [1]
Hepatic fibrosis DISECZYI DB93.0 Preclinical [1]
------------------------------------------------------------------------------------

References

1 Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24.